OVER / UNDER
KXFDARETATRUTIDE-RET ★ KALSHI ★ MULTI ★ KXFDARETATRUTIDE-RET ★ KALSHI ★ MULTI ★ KXFDARETATRUTIDE-RET ★ KALSHI ★ MULTI ★ KXFDARETATRUTIDE-RET ★ KALSHI ★ MULTI ★ KXFDARETATRUTIDE-RET ★ KALSHI ★ MULTI ★ KXFDARETATRUTIDE-RET ★ KALSHI ★ MULTI ★

Will the FDA approve retatrutide?

Price history — Before Jan 1, 2029

Last 7 days of market YES price (blue) with the fair-price range (orange).

92¢0¢25¢50¢75¢100¢Sat 5/30Sun 5/31Mon 6/1Tue 6/2Wed 6/3TODAY
━ market YES▬ fair range
Market price
Before Jan 1, 2029★ BEST92¢
Before Jul 1, 202887¢
Before Jan 1, 202884¢
Before Jul 1, 202764¢
Before Jan 1, 202723¢
Kalshi • Volume: 9.6K contracts • Updated 3h agoCloses: 2029-01-01
Kalshi · Science and Technology
OU's Pick
YES · Before Jan 1, 2029
at 92¢
Price gap
Kalshi92¢
→
OU's fair95¢
+3¢ underpriced · pays 1.1×
Confidence
Moderate

Phase 3 clinical trials for retatrutide are expected to conclude in early 2026 with a potential FDA approval timeline extending into late 2027 or early 2028.

Not financial advice. For informational purposes only. Prediction markets involve risk of loss. AI may contain errors.